^
    Back
    Association details:
    Biomarker:MECOM rearrangement
    Cancer:Myelodysplastic Syndrome
    Drug:sabatolimab (MBG453) (TIM-3 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASH 2023
    Title:

    4213 Clinical Characteristics and Outcomes of Myeloid Neoplasms with Mecom Rearrangement: Results from a Nationwide Multicenter Study

    Published date:
    11/02/2023
    Excerpt:
    Among 3 MDS with MECOM rearrangement, one patient received azacitidine with investigational drug (sabatolimab/placebo) and achieved complete hematologic response.
    Secondary therapy:
    azacitidine